Haemopep Pharma Gmbh

Ipf Pharmaceuticals Gmbh

Boehringer Mannheim Gmbh

Viro Pharmaceuticals Gmbh & Co. Kg

Knut Adermann

Wolf-Georg Forssmann

Frank Kirchhoff

Jan Münch

Ludger Ständker

Peter Schulz-Knappe

Hans-Dieter Zucht

Franz Herbst

Cornelia Liepke

Manfred Raida

Dieter Hock

Michael Gagelmann

Axel Schulz

Susann Baxmann

Elke Rücker

Hans-J&uuml;rgen M&auml;gert

Markus Magerlein

Hansueli Immer

Christian Klessen

Subject of the invention are peptides corresponding to a fragment of amino acids 240-290 of human prostatic acid phosphatase. The invention also relates to nucleic acids, antibodies, medicaments and diagnostics and their use and use of the peptides for the treatment and diagnosis of viral diseases, especially HIV disease.

Human semen enhancer of viral infection peptides (SEVI) and their use

The invention relates to peptides with biological activity against infection having the amino acid sequence Z-LE-X-IP-X-X-X-P-X-X-X-X-X-X-K-X-X-X-X-X-Z, wherein Xis a lysine, alanine, or aspartic acid; Xis a cysteine, methionine or isoleucine; Xis a serine, cysteine, lysine or glycine; Xis an isoleucine, alanine, phenylalanine or cysteine; Xis a proline, D-proline or a substituted L- or D-proline; Xis a cysteine or glutamic acid; Xis an amino acid with a hydrophobic or an aromatic side chain or cysteine; Xis an amino acid with a hydrophobic or an aromatic side chain or cysteine; Xis an amino acid with an aromatic side chain; Xis a glycine, alanine or asparagine; Xis a proline, aspartic acid, octahydroindolyl-2-carboxylic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; Xis a phenylalanine, alanine, glycine, glutamic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; Xis an amino acid with a hydrophobic or an aromatic side chain; Xis an amino acid with a hydrophobic or an aromatic side chain; Xis a phenylalanine or deletion; Zis NHor a sequence of 1 to 10 amino acid residues; Zis COOH or a sequence of 1 to 10 amino acid residues; and peptides which are fragments and/or covalently linked oligomers and/or derivatives, especially amidated, alkylated, acylated, sulfated, pegylated, phosphorylated and/or glycosylated derivatives, and mutants thereof, and with the provisio that (a) if Xis alanine, glycine, glutamic acid, or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid than X, Xand Xare phenylalanine, valine and phenylalanine respectively; and/or (b) if Xis phenylalanine, than X, Xand Xare valine, phenylalanine and a deletion, respectively; and (c) that there are at maximum two cysteine residues in a peptide.

Peptides and their use for the treatment of HIV infections

The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.

Antimicrobial bolisin peptides

Antibiotic peptides from bovine milk

Antibodies that bind peptides from the hPTH sequence (1-37)

Process for preparing cardiodilatin fragments; highly purified

The invention relates to a peptide from human blood, designated as hPTH-(1-37), the structure of which was elucidated for the purpose of the diagnostic, medical and commercial utilization thereof. The isolation of a fragment hPTH-(38-84) proves the existence of the hPTH-(1-37). A removal of amino-terminal amino acids from the hPTH fragment-(1-37) reduces its biological activity. The hPTH-(1-37) circulating in the blood is identical with the synthetic reference substance hPTH-(1-37), however not with fragments such as hPTH-(1-33), hPTH-(1-34) or hPTH-(1-38). The molecule form hPTH-(1-37) has been proven by mass spectrometry (plasma desorption method). A different biological activity and differences in the three-dimensional peptide structure of the hPTH fragment-(1-37) in comparison to other hPTH fragments furnish evidence of that this fragment is the preferential natural peptide of the parathormone family which should be used for the treatment of diseases of the parathyroid, circulatory system, respiratory system, male genital organ and kidneys.

HPTH-fragment-(1-37), the preparation thereof, medicaments containing

Growing community of inventors

Hannover, Germany

Knut Adermann